198 related articles for article (PubMed ID: 37598705)
1. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
[TBL] [Abstract][Full Text] [Related]
2. Moxidectin: an oral treatment for human onchocerciasis.
Milton P; Hamley JID; Walker M; Basáñez MG
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787
[TBL] [Abstract][Full Text] [Related]
3. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
Turner HC; Walker M; Attah SK; Opoku NO; Awadzi K; Kuesel AC; Basáñez MG
Parasit Vectors; 2015 Mar; 8():167. PubMed ID: 25889256
[TBL] [Abstract][Full Text] [Related]
4. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
[TBL] [Abstract][Full Text] [Related]
5. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
6. Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.
Turner HC; Walker M; Churcher TS; Osei-Atweneboana MY; Biritwum NK; Hopkins A; Prichard RK; Basáñez MG
Clin Infect Dis; 2014 Oct; 59(7):923-32. PubMed ID: 24944228
[TBL] [Abstract][Full Text] [Related]
7. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
[TBL] [Abstract][Full Text] [Related]
8. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
Awadzi K; Opoku NO; Attah SK; Lazdins-Helds J; Kuesel AC
PLoS Negl Trop Dis; 2014 Jun; 8(6):e2953. PubMed ID: 24968000
[TBL] [Abstract][Full Text] [Related]
9. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.
Stolk WA; Walker M; Coffeng LE; Basáñez MG; de Vlas SJ
Parasit Vectors; 2015 Oct; 8():552. PubMed ID: 26489937
[TBL] [Abstract][Full Text] [Related]
10. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
11. The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group.
NTD Modelling Consortium Onchocerciasis Group
Gates Open Res; 2019; 3():1545. PubMed ID: 31723729
[TBL] [Abstract][Full Text] [Related]
12. Vector control and entomological capacity for onchocerciasis elimination.
Tirados I; Thomsen E; Worrall E; Koala L; Melachio TT; Basáñez MG
Trends Parasitol; 2022 Jul; 38(7):591-604. PubMed ID: 35379556
[TBL] [Abstract][Full Text] [Related]
13. Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration.
Efon-Ekangouo A; Nana-Djeunga HC; Nzune-Toche N; Dongmo-Yemele R; Bopda J; Ongbassomben V; Sumo L; Geiger A; Nutman TB; Kamgno J
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011250. PubMed ID: 37058547
[TBL] [Abstract][Full Text] [Related]
14. Research for new drugs for elimination of onchocerciasis in Africa.
Kuesel AC
Int J Parasitol Drugs Drug Resist; 2016 Dec; 6(3):272-286. PubMed ID: 27693536
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin.
Otabil KB; Ankrah B; Bart-Plange EJ; Donkoh ES; Avarikame FA; Ofori-Appiah FO; Babae TN; Kudzordzi PC; Darko VA; Ameyaw J; Bamfo JG; Sakibu RA; Antwi-Berko D; Fodjo JNS; Basáñez MG; Schallig HDFH; Colebunders R
Infect Dis Poverty; 2023 Aug; 12(1):75. PubMed ID: 37587500
[TBL] [Abstract][Full Text] [Related]
16. River Blindness: Mathematical Models for Control and Elimination.
Basáñez MG; Walker M; Turner HC; Coffeng LE; de Vlas SJ; Stolk WA
Adv Parasitol; 2016; 94():247-341. PubMed ID: 27756456
[TBL] [Abstract][Full Text] [Related]
17. Differential susceptibility of Onchocerca volvulus microfilaria to ivermectin in two areas of contrasting history of mass drug administration in Cameroon: relevance of microscopy and molecular techniques for the monitoring of skin microfilarial repopulation within six months of direct observed treatment.
Abong RA; Amambo GN; Chounna Ndongmo PW; Njouendou AJ; Ritter M; Beng AA; Esum ME; Deribe K; Fru-Cho J; Fombad FF; Nji TM; Enyong PI; Poole CB; Pfarr K; Hoerauf A; Carlow CKS; Wanji S
BMC Infect Dis; 2020 Oct; 20(1):726. PubMed ID: 33008333
[TBL] [Abstract][Full Text] [Related]
18. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
19. Elimination of onchocerciasis in Ecuador: findings of post-treatment surveillance.
Guevara Á; Lovato R; Proaño R; Rodriguez-Perez MA; Unnasch T; Cooper PJ; Guderian RH
Parasit Vectors; 2018 Apr; 11(1):265. PubMed ID: 29690907
[TBL] [Abstract][Full Text] [Related]
20. Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda.
Jacob BG; Loum D; Lakwo TL; Katholi CR; Habomugisha P; Byamukama E; Tukahebwa E; Cupp EW; Unnasch TR
PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006702. PubMed ID: 30148838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
